Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Mai 2020 07:00 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Announces First Quarter 2020 Results and Update

Patient dosing initiated in BRILLIANCE Phase 1/2 trial of EDIT-101 (AGN-151587) for LCA10 On track to file IND for EDIT-301 for sickle cell disease by end of 2020 Initiated IND-enabling studies for...
30. April 2020 08:05 ET | Quelle: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing First Quarter 2020 Results and Corporate Update

CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
29. April 2020 09:00 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers

CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the initiation of IND-enabling activities for EDIT-201,...
04. März 2020 05:00 ET | Quelle: Editas Medicine, Inc.; Allergan plc

Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10

AGN-151587 (EDIT-101) is the first in vivo CRISPR medicine to be administered to patients Additional patient enrollment to the BRILLIANCE Clinical Trial is ongoing DUBLIN, Ireland and CAMBRIDGE,...
26. Februar 2020 16:02 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update

Announcement of first patient dosing with EDIT-101 (AGN-151587) expected in 1Q20 Plan to file IND for EDIT-301 for sickle cell disease by end of 2020 Research collaboration with Sandhill...
19. Februar 2020 16:02 ET | Quelle: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2019 Results and Corporate Update

CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
13. Januar 2020 09:00 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference

Provides updates on advancements in in vivo and engineered cell medicine programs Details timeline to filing an IND for EDIT-301 for the treatment of sickle cell disease CAMBRIDGE, Mass., Jan. 13,...
13. Januar 2020 08:55 ET | Quelle: Editas Medicine, Inc.

Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

CAMBRIDGE, Mass. and DALLAS, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Sandhill Therapeutics, Inc., a cellular immuno-oncology...
10. Januar 2020 16:30 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Reports Inducement Grants to New Chief Financial Officer

CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly...
09. Januar 2020 09:00 ET | Quelle: Editas Medicine, Inc.

Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth

Michelle Robertson joins as Chief Financial Officer Manufacturing veteran Harry Gill joins in newly created role of Senior Vice President, Operations CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE...

Vorherige Seite